Navigation Links
Pregis Announces First Quarter 2008 Financial Results
Date:5/9/2008

s, net

sales for the segment decreased 1.4% in the quarter, due mainly to

product mix during the quarter.

A summary of a significant measure required by the Company's indentures is presented in the supplemental information at the end of this release.

Conference Call:

The Company will conduct an investor conference call to review its 2008 first quarter results on Monday, May 12, 2008 at 10:00 a.m. ET (9:00 a.m. CT). The call can be accessed through the following dial-in numbers: Domestic: 866-510-0708; International: 617-597-5377; Participant Passcode: 95937816. A replay of the conference call will be available through May 23, 2008. The replay may be accessed using the following dial-in information: Domestic: 888-286-8010; International: 617-801-6888; Passcode: 73894836.

About Pregis:

Pregis Corporation is a leading global provider of innovative protective, flexible, and foodservice packaging and hospital supply products. The specialty-packaging leader currently operates 47 facilities in 18 countries around the world. Pregis Corporation is a wholly owned subsidiary of Pregis Holding II Corporation. For more information about Pregis, visit the Company's web site at http://www.pregis.com.

Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by the Company's use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which
'/>"/>

SOURCE Pregis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Pregis Corporation Appoints New President of Protective Packaging North America
2. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
3. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...ombining natural organic atoms with metal complexe...ed a new type of enzyme inhibitor capable of block... cancer development. , Based on studies in huma...eveloping new ways to treat cancer by dampening th...olled tumor growth. , Details of the study, to b...
(Date:5/15/2008)...ay 15 /PRNewswire-FirstCall/ -- Lung cancer patien...sions may fare better as a,result, according to da...C),clinical trial. Data from the trial, which invo... for injection), will be presented at the 44th Ann...cology (ASCO) in Chicago,Ill., May 30 -- June 3, ...
(Date:5/15/2008)...ity-control audit of community hospitals associate...gests that a partnership between a major academic ...are created, and community hospitals, where most c...uickly and effectively disseminating advances in c...d Comprehensive Cancer Center in Philadelphia, fir...
(Date:5/15/2008)...motherapy given in conjunction with cancer vaccine...ly improving the effectiveness of this promising t...earchers in the Duke Comprehensive Cancer Center. ...ls that suppress immune function and we speculated...used in conjunction with vaccines, which work by b...
Breaking Medicine News(10 mins):Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 2Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 3Health News:Chemotherapy might help cancer vaccines work 2
...s from 19 countries holding an international summi...nion that culls of wild birds are not an answer t...anised by the Avian Flu Task Force under the UN in...nal convention on migratory species. Despite the...
...ts that smoking is more common in the gay communit...re calling for more research to document this diff...ulation were less likely to be smokers than a samp...emselves as lesbian, gay or bisexual (LGB), accord...
...s claimed that 'Harry Potter is dead'. Hackers ha...tter-TheDeathlyHallows.doc', the title of JK Rowl... known as Hairy-A - works by infecting USB memory ...puters where users have unwittingly downloaded the...
... (OTC Bulletin Board: AVGO), a late stage biotechn... therapeutics for neurodegenerative diseases, anno...D-02, its novel drug candidate for the treatment ...s determined in an open-label dose escalation stud...
Other Medicine News:Health News:Gays, Lesbians, Bisexuals Smoke More Than General Population in California 2Health News:Avicena to Advance Huntington's Disease Clinical Program into Phase III 2
(Date:5/15/2008)... GREEN BAY, Wis., May 15 /- Omeg... be further considered as a credible natural,alter...ty in ADHD patients,recent in vivo French study r...cial effects of omega-3 in hyperactivity, French r...ld have specific positive effects on,impulse contr...
(Date:5/14/2008)... CAMBRIDGE, Mass., May 14 /PRNewswire-FirstCa...announced that the results from its Phase II coron... the peer-reviewed,EuroIntervention Journal. The p...te haemoglobin based oxygen therapeutics in electi...ale, protocol design, and haemodynamic,results." T...
(Date:5/14/2008)... Believed by experts to be important for cer...RNewswire-FirstCall/ -- New data from an,extended ...GSK ) cervical,cancer candidate vaccine, CERVARIX(... antibodies against the two most common cervical c... 6.4 years. This is the longest,duration of sustai...
(Date:5/14/2008)... Data Presented at the American Society of Hyp...ual Scientific Meeting - A cumulative forty-fiv...nsion treated with a regimen of BENICAR(R) (olmesa...medoxomil/hydrochlorothiazide) achieved ... Eight out of 10 (cumulative 81%) patients with st...
Breaking Medicine Technology:Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 2Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Weill Cornell science briefs May 2008 19346 1Weill Cornell science briefs May 2008 19346 2Weill Cornell science briefs May 2008 19346 3Weill Cornell science briefs May 2008 19346 4Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 1Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 2Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 3Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 4Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 5Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 6Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 7Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 8Saia Partners with Susan G Komen for the Cure 19339 1Saia Partners with Susan G Komen for the Cure 19339 2Saia Partners with Susan G Komen for the Cure 19339 3Milliman Says 2008 Medical Cost for American Family of Four Exceeds 2415 600 19334 1Milliman Says 2008 Medical Cost for American Family of Four Exceeds 2415 600 19334 2
...007 /PRNewswire-FirstCall/ -- Kosan,Biosciences In...,proprietary nuclear export inhibitors (NEI) showi...ng anticancer activity with a,high degree of toler...odels. , Kosan,s NEIs are potent, specific inhibit... that exports key regulatory proteins,("cargo" pro...
...sion Proteins Made by Combining,Cytokines With Per...Anti-Tumor Activity With No Observable Toxicity -,...RNewswire-FirstCall/ -- Peregrine Pharmaceuticals,... developing targeted,monoclonal antibodies for the...on, today reported that data presented at the,Cent...
Other Medicine Technology:Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 4Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 2Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 3Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 4
...hysiology imaging have become more acute. The nee...exposure to both patient and staff has become para...ems. In keeping with Omegas goal of maintaining i..., four bi-plane imaging configurations are availab...
...ice efficiency by reducing errors and eliminating ...diology software solution, you can spend less time... time on your patient care. Cardiology software fr...r 50,000 installations and a long track record of ...
...ates an integrated Medical Records and Transcripti...d by the national Health Care HL7 communications p...ormation insurers and physician inter-office commu...ectronic exchange of Patient medical records, Demo...
... is a Web Browser-based Ambulatory software suite ...tronic Medical Record (EMR) and Managed Care solut...and for dependable HIPAA-era management software, ... software products and services that provide a sec...
Medicine Products: